JUN 16, 2021 7:25 AM PDT

New drug attacks pancreatic tumors with mutant KRAS addiction

Pancreatic cancer is notoriously difficult to detect in early stages, which is why it is associated with a low survival rate. Now a study published in Clinical Cancer Research identifies a drug that is capable of derailing pancreatic tumors that are dependent on the mutant KRAS gene.

Approximately 90% of pancreatic cancers harbor mutant KRAS and some tumors have even been shown in previous studies to be unable to survive without the gene – what’s called a mutant KRAS addiction. Watch the video below to learn more about the KRAS gene and how it causes cancer.

In researching mutant KRAS addition, Said Sebti, Ph.D., who is associate director for basic research at VCU Massey Cancer Center, discovered a drug that can kill pancreatic tumors with mutant KRAS addiction. "We discovered a link between hyperactivation of the CDK protein and mutant KRAS addiction, and we exploited this link preclinically to counter mutant KRAS-driven pancreatic cancer, warranting clinical investigation in patients afflicted with this deadly disease," said Sebti. "Our findings are highly significant as they revealed a new avenue to combat an aggressive form of pancreatic cancer with very poor prognosis due mainly to its resistance to conventional therapies."

"Using three entirely different approaches, the same conclusion presented itself clearly to us: pancreatic cancer patients whose tumors are addicted to mutant KRAS could benefit greatly from treatment with the CDK inhibitor AT7519," Sebti adds.

Further tests showed that AT7519 was also able to suppress the growth of xenograft cells from five mutant KRAS pancreatic cancer patients who had not experienced success with chemotherapy and/or radiation. Next, the researchers hope to test out AT7519 in clinical trials targeting pancreatic cancer.

"If our findings are correct and translate in humans, then we should be able to see a positive response in pancreatic cancer patients whose tumors are addicted to mutant KRAS," Sebti said.

Sources: Clinical Cancer Research, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
APR 19, 2021
Health & Medicine
Using Artificial Intelligence to Understand the Language of Cancer and Alzheimer's Disease
APR 19, 2021
Using Artificial Intelligence to Understand the Language of Cancer and Alzheimer's Disease
Cancer and Alzheimer’s disease are life-changing, and there is still much we don’t understand about what cau ...
APR 24, 2021
Technology
'Information Theory' Detects Culprit Cancer Genes
APR 24, 2021
'Information Theory' Detects Culprit Cancer Genes
A team of scientists at Johns Hopkins used “information theory” to uncover key cancer genes. One such culpri ...
MAY 04, 2021
Clinical & Molecular DX
Vibrating Needles Make for Better Biopsies
MAY 04, 2021
Vibrating Needles Make for Better Biopsies
  To understand what’s going on with a patient, doctors may take a biopsy—a sample of tissue extracted ...
MAY 27, 2021
Microbiology
Some Microbes May Protect the Gut From Chemo's Harmful Effects
MAY 27, 2021
Some Microbes May Protect the Gut From Chemo's Harmful Effects
The microbes in our gut can influence our physiology in many ways. Some gut microbes have a positive impact on human hea ...
JUN 06, 2021
Cancer
New drug reduces tumor size in lung cancer patients with KRAS gene mutation
JUN 06, 2021
New drug reduces tumor size in lung cancer patients with KRAS gene mutation
The most recent results from the CODEBREAK 100 phase 2 clinical trial support the use of the drug sotorasib to reduce tu ...
JUL 12, 2021
Cell & Molecular Biology
A Molecule From the Gut Microbiome May Fight Tumors
JUL 12, 2021
A Molecule From the Gut Microbiome May Fight Tumors
The more we learn abut the gut microbiome, the more it seems that the microorganisms in our gastrointestinal tracts can ...
Loading Comments...